Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma

Abstract

An in vitro assay to quantify melphalan-induced p53-specific damage formation/repair can be used to select those patients with MM who are more likely to benefit from HDM supported by ASCT.